Search

Scientists have discovered tumors can tap a nontraditional pathway to acquire lipoproteins – molecules that transport fat in blood – which enriches cancer cells with an antioxidant shield to survive stress, according to new research from Children’s Medical Center Research Institute at UT

UT Southwestern researchers find that humans and mice with pancreatitis are deficient in a stress hormone called FGF21.

UT Southwestern Medical Center has received an award from the Advanced Research Projects Agency for Health (ARPA-H) to develop livers using patients’ own cells and an innovative three-dimensional (3D) printing approach.

An artificial intelligence (AI)-based model developed by UT Southwestern Medical Center researchers can accurately predict which kidney cancer patients will benefit from anti-angiogenic therapy, a class of treatments that’s only effective in some cases.

Expanded telehealth services at UT Southwestern have proved effective at safely delivering patient care during the pandemic, leading to an increase in patients even in specialties such as plastic surgery, according to a new study.

UT Southwestern Communications tells stories about the extraordinary work being done here every day and about the dedicated, passionate people behind it. Explore these stories.

Russell DeBose-Boyd, Ph.D., Professor of Molecular Genetics at UT Southwestern Medical Center, has been awarded the Hill Prize in Biological Sciences from the Texas Academy of Medicine, Engineering, Science and Technology (TAMEST) in recognition of his long-standing research into a key mechanism

The ultimate cause of death from cancer isn’t metastatic disease, as researchers have long surmised, but an infiltration of tumors into major blood vessels that cause blood clots and multiorgan failure, a one-of-a-kind clinical study led by UT Southwestern Medical Center suggests.

Elevated calcium levels in the blood – a complication of kidney cancers known as hypercalcemia – may be successfully treated with a class of medications called HIF-2 inhibitors developed by UT Southwestern Medical Center, a new study shows. The findings, published in Cancer Discovery by a team at

UTSW research finds significant disparities exist in diagnosing and treating headaches by race, socioeconomic level, and insurance status.